Cancer is a complex disease resulting from the interplay between the tumor cell and its microenvironment, featuring impaired apoptosis and activation of quiescent blood vessels to induce neovascularization to support metastasis. Two of the yet unmet needs in anticancer therapy are how to restore apoptosis and to abrogate metastatization.
We identified first-in-class OPA1 inhibitors with anti-cancer properties to overcome drug resistance, e.g., to Venetoclax and VEGF ligands, and thus treat cancer such as acute amyloid leukemia (AML) by specific induction of apoptosis and restriction of cancer angiogenesis.
OPA1 is mitochondrial dynamin like GTPase upregulated in several cancers where it prevents apoptosis, and its expression is correlated unfavorable prognosis. It is required for cancer angiogenesis and is responsible for Venetoclax resistance in AML.

TRL

Lead Optimization/Preclinical

Inventors

Luca
Scorrano

Franziska
Charlotte
Quirin

Anna
Pellattiero

Download the brochure

  • Use of small molecules to rescue folding defective proteins

    The use of CFTR (cystic fibrosis transmembrane conductance regulator) correctors for the treatment of rare and devastating genetic muscular diseases, namely sarcoglycanopathies and Brody myopathy, is the object of this invention. Sarcoglycanopathies and Brody myopathy are rare inherited striated muscle[...]

  • Tioridazine analogues for acute myeloid leukemia treatment

    Specific treatments for (pediatric) acute myeloid leukemia (AML) are lacking. Standard treatments still include intensive myelosuppressive chemotherapy, which is unsatisfactory in terms of general toxicity, with the persistent risk of relapse due to the escape of quiescent leukemic cells to[...]

  • Novel treatment to mitigate the Ectrodactyly-Ectodermal dysplasia- Clefting (EEC) associated blindness

    The Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome is a rare genetic disorder due to mutations in the p63 gene and characterized by limb defects, orofacial clefting, ectodermal dysplasia, and ocular surface defects that lead to the loss of vision. Currently no specific[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation